Biogen Idec Gains Phase II MS, Cancer Biologics Through PDL Deal
The agreement gives Biogen rights to Protein Design Labs' daclizumab, volociximab and fontolizumab.
The agreement gives Biogen rights to Protein Design Labs' daclizumab, volociximab and fontolizumab.